Secondary Cushing's syndrome in children with juvenile idiopathic arthritis following intra-articular triamcinolone acetonide administration SIR, Intra-articular corticosteroid injection is a widely used treatment in the management of juvenile idiopathic arthritis (JIA) that generally induces rapid resolution of synovitis [1] . Triamcinolone hexacetonide (TH) is the preferred drug, with sustained symptom relief over longer periods than triamcinolone acetonide (TA) [2] [3] [4] . However, due to recent difficulties in obtaining TH, TA was used in our unit as an alternative agent. One hundred and ninety-five children (362 joints) and 180 children (216 joints) received intra-articular TH and TA, respectively, over a 3-yr period. Visibly prominent Cushing's syndrome developed in nine (5%) of the children who had received TA. The clinical details are summarized in Table 1 . Intra-articular steroid injection is safe and effective in the management of JIA in children. Excessive weight gain and cushingoid appearance have been reported in adults and children following intra-articular TA injections but not with TH [5, 6] . Huppertz and Pfuller [7] reported transient suppression of endogenous cortisol release, detected by a low morning peak value of salivary cortisol, with no adverse events noted. Adrenocortical insufficiency was not formally assessed in our patient group. We did not observe a cushingoid state with TH even when multiple joints were injected, but accept that very minor weight gain or less prominent features, such as transient flushing of the cheeks, may not have been detected by this retrospective review. The development of a cushingoid state does not appear to be related to sex, age, current therapy or the type of arthritis. Although most of the children we report had multiple intra-articular injections (up to eight joints at a time with a cumulative TA dose of up to 14.5 mg/kg), Cushing's syndrome still occurred in three children who had only one or two joints injected (cases 5, 7 and 8). In our experience this side-effect was distressing for both carers and patients, although spontaneous resolution occurred, albeit over a variable period (no greater than 5 months in any patient). The resolution of hypercortisolism has been reported elsewhere to last up to 8 months [6] . We did not collect systematic data relating to the time of resolution in our patients, but none was greater than 5 months.
We undertook a separate study comparing the efficacy of 256 injections with TH and 113 with TA during the period when TH was unavailable, noting similar remission rates of 83% with TH and 87% with TA. Time to reinjection was 6.16 months with TA compared with 8.7 months for TH [8] .
A cushingoid state is not uncommon after intra-articular administration of TA, including after injection of a single joint. Patients and carers should be counselled accordingly before treatment. We advocate TH as the therapy of choice because of its longer duration of action but, notwithstanding the adverse effect reported, our experience would support the use of TA as an effective alternative agent if TH is not available.
SIR, A 36-yr-old Caucasian female supermarket worker presented with increasing fatigue, dry cough, wheeze, drenching night sweats and weight loss. On examination she had multiple spider naevi and gross hepatomegaly. Investigation showed abnormal liver function tests with raised alkaline phosphatase 400 IU/l (31-116) and -glutamyl transferase 400 IU/l (0-72). Other liver function tests were normal, as were hepatitis, cytomegalovirus and human immunodeficiency virus serology. Strikingly, she had an eosinophilia of 10 Â 10 9 /l with an erythrocyte sedimentation rate (ESR) of 95 mm/1st hour (0-15) and a C-reactive protein (CRP) of 40 mg/l (0-7). Computed tomography (CT) scanning showed hepatomegaly, the left lobe of the liver displacing the stomach, and hypoattenuation suggestive of periportal oedema with an enlarged lymph node in the porta hepatis (Fig. 1a) ; no other lymphadenopathy was seen on whole-body CT. All tumour markers, antinuclear and mitochondrial antibodies were negative. Smooth muscle antibody was weakly positive (1:80) and thyroid antibodies were positive, with normal thyroid function. She had never left the UK, had no contact with farm animals and an extensive infection screen for parasitic and other infectious causes was negative.
A positron emission tomography scan showed intense abnormal uptake in the liver and less specific uptake in the inframammary and bone marrow areas. A bone marrow showed reactive features with negative cytogenetics, making a myeloproliferative disorder unlikely. Two percutaneous liver biopsies and a mini-laparotomy with wedge biopsy and portal node biopsy were performed. The liver biopsies excluded lymphoma but all showed necrotizing granulomas with infiltration of eosinophils. There were no features of vasculitis or bacterial, fungal or tuberculous infections.
Churg-Strauss syndrome (CSS) was considered and a perinuclear antineutrophil cytoplasmic antibody test (p-ANCA) was weakly positive, with proteinase 3 antibodies in low titre [12 IU/ml (0-10)] but a diagnosis of hypereosinophilic syndrome (HES) was felt more likely. Diagnostic criteria for HES [1] include the presents of persistent eosinophilia of 1.5 Â 10 9 /l for longer than 6 months, lack of evidence for parasitic, allergic or other known causes of eosinophilia, and signs and symptoms of organ involvement. A significant percentage of HES patients have cryptic rearrangements of the PDGF receptor A gene, resulting in constitutive activation of this receptor with tyrosine kinase. These patients are sensitive to STI 571(Glivec), a tyrosine kinase inhibitor well known for its activity in chronic myeloid leukaemia. This patient did not have the gene rearrangement but her eosinophils were sensitive to STI 571 so she was started on 400 mg daily.
There was, however, no improvement in her symptoms or eosinophilia, so she was referred to the St Thomas' Hospital vasculitis clinic. Here her history revealed late-onset asthma and
